Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Simcere Pharmaceutical Group

http://en.simcere.com/

Latest From Simcere Pharmaceutical Group

Next Allergy Blockbuster? GI Innovation Shares Why It Is Confident

Bookmark
  • Interviews
By Jung Won Shin

GI Innovation chairman and CEO B G Rhee talks about his ambitions for the Korean bispecific protein firm’s leading allergy and immuno-oncology pipeline assets and what is behind his confidence.

South Korea Clinical Trials

Pharma Execs: China Slowly Returning To Growth But Uncertainty Remains

Bookmark
  • Analysis
By Brian Yang and Dexter Yan

Just how dynamic is the China market for multinationals? AstraZeneca is seeing growth returning while Pfizer is finding it challenging to estimate Paxlovid demand, Sanofi is encouraged by volume gains and GSK is predicting a "sizeable" rebound. Top executives from Novartis and Roche also shed light on other challenges facing global pharma firms in the world's second-largest pharma market as they reported annual results.

China Commercial

China Approves Two More Home-Grown COVID-19 Antivirals

Bookmark
  • Analysis
By Dexter Yan

Top-line results for two newly approved COVID-19 antivirals in China showed roughly 1.5- to two-day cuts in median time to symptom resolution or recovery in mild-to-moderate Omicron patients versus placebo.

China Approvals

Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics

Bookmark
  • News
By Anju Ghangurde, Joseph Haas, Ian Haydock, Jung Won Shin, Lisa Takagi, Dexter Yan and Brian Yang

Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Jilin Boda Pharmaceutical Co., Ltd.
    • ChinaVax
    • Master Luck Corporation Limited
    • Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
    • Jiangsu Yanshen Biological Technology Stock Co., Ltd.
    • Nanjing Tung Chit Pharmaceutical Co., Ltd.
    • Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd.
    • Wuhu Zhong Ren Pharmaceutical Co. Ltd.
    • Xiangao Investment Company Ltd.
    • Yantai Medgenn Co. Ltd.
    • Jiangsu Simcere Pharmaceutical Co., Ltd.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By